Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24554756 | 0.83 | PLAU (0.39) | PLAU | |
| Trifluoroacetic Acid SCHEMBL29681764 | 0.76 | THRA (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL29109294 | 0.76 | THRA (0.31) | — | |
| SCHEMBL28980313 | 0.70 | LMNA (0.35) | PLAU | |
| Trifluoroacetic Acid SCHEMBL3149138 | 0.69 | HRH4 (0.41) | CA12CA1CA2CA9HRH4 | |
| Trifluoroacetic Acid SCHEMBL10619788 | 0.69 | HRH4 (0.41) | CA12CA1CA2CA9HRH4 | |
| Trifluoroacetic Acid SCHEMBL6382776 | 0.67 | TAAR1 (0.68) | CA12CA1CA2CA9 | |
| Trifluoroacetic Acid SCHEMBL11052838 | 0.66 | HRH4 (0.40) | CA12CA1CA2CA9HRH4 | |
| Trifluoroacetic Acid SCHEMBL668082 | 0.65 | CA12 (0.56) | CA12CA1CA2CA9 | |
| Trifluoroacetic Acid SCHEMBL7710331 | 0.64 | CA12 (0.37) | CA12CA1CA2CA9HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317775-A1 | H4 Antagonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| EP-4259637-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116848125-A | H4 antagonist compounds | 赫帕雷斯治疗有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022129890-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317775-A1 | H4 Antagonist Compounds | HRH4, HRH3, H1-4 | PLAU 3023/4885CA12 4623/4885CA1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.